Association between MDR1 C3435T polymorphism and risk of breast cancer

Gene

Volumn 532, Issue 1, 2013, Pages 94-99

  Wang, Zhaoming ^a   Wang, Ting ^a   Bian, Jianmin ^b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; MDR1; Meta analysis

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN 1;

ARTICLE; ASIAN; BREAST CANCER; CANCER RISK; CAUCASIAN; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; META ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ABCB1; ADENOSINE TRIPHOSPHATE; ATP; ATP-BINDING CASSETTE SUB-FAMILY B GENE 1; BREAST CANCER; CI; CONFIDENCE INTERVALS; HARDY-WEINBERG EQUILIBRIUM; HWE; MALDI-TOF MS; MATRIX-ASSISTED LASER DESORPTION/IONIZATION TIME-OF-FLIGHT MASS SPECTROMETRY; MDR; MDR1; META-ANALYSIS; MULTI-DRUG RESISTANCE; MULTI-DRUG RESISTANCE GENE 1; ODDS RATIO; OR; P-GLYCOPROTEIN; P-GP; PCR; PCR-RFLP; POLYMERASE CHAIN REACTION; POLYMERASE CHAIN REACTION-RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE-NUCLEOTIDE POLYMORPHISM; SNP; TP53; TUMOR PROTEIN GENE 53;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; PUBLICATION BIAS;

EID: 84885376019     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.09.050     Document Type: Article

References (30)

1. Abbas S., et al. Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women. Breast Cancer Res. Treat. 2010, 120(3):727-736.
2. Breier A., et al. P-glycoprotein-implications of metabolism of neoplastic cells and cancer therapy. Curr. Cancer Drug Targets 2005, 5(6):457-468.
3. Brinkmann U., Roots I., Eichelbaum M. Pharmacogenetics of the human drug-transporter gene MDR1: impact of polymorphisms on pharmacotherapy. Drug Discov. Today 2001, 6(16):835-839.
4. Cizmarikova M., et al. MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. Pharmacogenomics J. 2010, 10(1):62-69.
5. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 1986, 7(3):177-188.
6. Egger M., et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315(7109):629-634.
7. George J., et al. A single-nucleotide polymorphism in the MDR1 gene as a predictor of response to neoadjuvant chemotherapy in breast cancer. Clin. Breast Cancer 2009, 9(3):161-165.
8. Gervasini G., et al. Adenosine triphosphate-binding cassette B1 (ABCB1) (multidrug resistance 1) G2677T/A gene polymorphism is associated with high risk of lung cancer. Cancer 2006, 107(12):2850-2857.
9. Handoll H.H. Systematic reviews on rehabilitation interventions. Arch. Phys. Med. Rehabil. 2006, 87(6):875.
10. Haros M., Bielecka M., Sanz Y. Phytase activity as a novel metabolic feature in Bifidobacterium. FEMS Microbiol. Lett. 2005, 247(2):231-239.
11. Henriquez-Hernandez L.A., et al. Gene polymorphisms in TYMS, MTHFR, p53 and MDR1 as risk factors for breast cancer: a case-control study. Oncol. Rep. 2009, 22(6):1425-1433.
12. Hoffmeyer S., et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U. S. A. 2000, 97(7):3473-3478.
13. Jamroziak K., et al. Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur. J. Haematol. 2004, 72(5):314-321.
14. Lo P.K., Sukumar S. Epigenomics and breast cancer. Pharmacogenomics 2008, 9(12):1879-1902.
15. Lu P.H., et al. Association between two polymorphisms of ABCB1 and breast cancer risk in the current studies: a meta-analysis. Breast Cancer Res. Treat. 2011, 125(2):537-543.
16. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 1959, 22(4):719-748.
17. Nordgard S.H., et al. ABCB1 and GST polymorphisms associated with TP53 status in breast cancer. Pharmacogenet. Genomics 2007, 17(2):127-136.
18. Rubis B., et al. Study of ABCB1 polymorphism frequency in breast cancer patients from Poland. Pharmacol. Rep. 2012, 64(6):1560-1566.
19. Sant M., et al. Time trends of breast cancer survival in Europe in relation to incidence and mortality. Int. J. Cancer 2006, 119(10):2417-2422.
20. Sheng X., et al. MDR1 C3435T polymorphism and cancer risk: a meta-analysis based on 39 case-control studies. Mol. Biol. Rep. 2012, 39(7):7237-7249.
21. Smith R.A., et al. Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening. CA Cancer J. Clin. 2013, 63(2):88-105.
22. Stavrovskaya A.A. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc.) 2000, 65(1):95-106.
23. Taheri M., Mahjoubi F., Omranipour R. Effect of MDR1 polymorphism on multidrug resistance expression in breast cancer patients. Genet. Mol. Res. 2010, 9(1):34-40.
24. Tatari F., et al. Association of C3435T single-nucleotide polymorphism of MDR1 gene with breast cancer in an Iranian population. DNA Cell Biol. 2009, 28(5):259-263.
25. Turgut S., et al. MDR1 C3435T polymorphism in patients with breast cancer. Arch. Med. Res. 2007, 38(5):539-544.
26. Wang J., et al. MDR1 gene C3435T polymorphism and cancer risk: a meta-analysis of 34 case-control studies. J. Cancer Res. Clin. Oncol. 2012, 138(6):979-989.
27. Wu H., et al. Roles of ABCB1 gene polymorphisms and haplotype in susceptibility to breast carcinoma risk and clinical outcomes. J. Cancer Res. Clin. Oncol. 2012, 138(9):1449-1462.
28. Yan Q., Wajapeyee N. Exploiting cellular senescence to treat cancer and circumvent drug resistance. Cancer Biol. Ther. 2010, 9(3):166-175.
29. Yuan H., et al. Strategies to overcome or circumvent P-glycoprotein mediated multidrug resistance. Curr. Med. Chem. 2008, 15(5):470-476.
30. Zhou S.F. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 2008, 38(7-8):802-832.